Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CCT 137690

Catalog No: tcsc0706

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1095382-05-0

Formula:
$C_{26}H_{31}BrN_8O$

Pathway:
Cell Cycle/DNA Damage;Epigenetics

Target:
Aurora Kinase;Aurora Kinase

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
551.48

Product Description

CCT 137690 is a potent and orally available **aurora** kinase inhibitor with **IC_{50}**s of 15, 25, and 19 nM for aurora A, B and C,

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

respectively.

IC50 & Target: IC50: 15 nM (Aurora A), 25 nM (Aurora B), 19 nM (Aurora C)[1]

In Vitro: CCT 137690 displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI_{50} =0.30 μM) and A2780 ovarian cancer cell line (GI_{50}=0.14 μM). CCT 137690 inhibits *in vitro* phosphorylation of histone H3. CCT 137690 is a moderate inhibitor of the hERG ion-channel (IC_{50}=3.0 μM)[1]. CCT137690 efficiently inhibits histone H3 and TACC3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumour cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy and apoptosis[2].

In Vivo: CCT 137690 slows the growth of the SW620 xenografts with no observed toxicity[1]. CCT 137690 significantly inhibits tumour growth in a transgenic mouse model of neuroblastoma (TH-MYCN) that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation[2].